https://www.oncologynurseadvisor.com Thu, 04 Jan 2024 20:12:21 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.3 https://www.oncologynurseadvisor.com/wp-content/uploads/sites/13/2024/01/cropped-CTA-ONA-HEM-favicon-32x32.png https://www.oncologynurseadvisor.com 32 32 https://www.oncologynurseadvisor.com/home/cancer-types/lung-cancer/first-line-benmelstobart-regimen-produces-longest-pfs-os-to-date-in-es-sclc/ Fri, 22 Sep 2023 14:30:00 +0000 https://www.oncologynurseadvisor.com/?p=110845 Adding benmelstobart and anlotinib to first-line chemotherapy improved survival outcomes in a phase 3 trial of patients with ES-SCLC. ]]> https://www.oncologynurseadvisor.com/home/cancer-types/lung-cancer/iruplinalkib-outperforms-crizotinib-in-alk-advanced-nsclc/ Wed, 20 Sep 2023 14:20:00 +0000 https://www.oncologynurseadvisor.com/?p=110713 Iruplinalkib, a novel ALK inhibitor, was more effective than crizotinib in a phase 3 trial of patients with advanced, ALK-positive non-small cell lung cancer.]]> https://www.oncologynurseadvisor.com/home/cancer-types/general-oncology/as-cancer-drug-shortages-increase-patients-lives-are-at-stake/ Fri, 14 Jul 2023 15:00:00 +0000 https://www.oncologynurseadvisor.com/?p=109263 Oncology leaders testified before a House subcommittee about how drug shortages are hindering cancer care in the US and threatening the lives of patients.]]> https://www.oncologynurseadvisor.com/home/cancer-types/lung-cancer/women-clinical-trials-nsclc-underrepresented/ Tue, 23 May 2023 14:20:00 +0000 https://www.oncologynurseadvisor.com/?p=107899 Women are underrepresented in clinical trials of NSCLC treatment, a meta-analysis suggests.]]> https://www.oncologynurseadvisor.com/home/cancer-types/lung-cancer/covid-19-nsclc-treatment-triple-risk-of-death/ Mon, 15 May 2023 14:40:00 +0000 https://www.oncologynurseadvisor.com/?p=107661 Patients with non-small cell lung cancer may have a 3-fold higher risk of death if they develop COVID-19, a study suggests.]]>